N/A
N=1,862
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
Chlamydia Trachomatis · Neisseria Gonorrhoeae Infection
Bottom Line
View on ClinicalTrials.gov: NCT01733069 ↗Enrolled (actual)
1,862
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcome: Primary: APTIMA Combo 2 Assay Accuracy Compared to Infected Status by Sample Type — 104; 18; 3; 1149 participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- APTIMA COMBO 2 Assay (AC2 Assay) (Device)
- Age
- Pediatric, Adult, Older Adult · 14+ yrs
- Sex
- All
- Sponsor
- Gen-Probe, Incorporated
- Primary completion
- Feb 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY APTIMA Combo 2 Assay Accuracy Compared to Infected Status by Sample Type |
104; 18; 3; 1149; 112; 0 | — |
Summary
The objectives of this study are to establish the performance characteristics of the AC2 (APTIMA Combo 2) Assay on the PANTHER System for the sample types cleared for use on the TIGRIS and DTS (Direct Tube Sampling) Systems and to demonstrate the repeatability and reproducibility of the AC2 Assay on the PANTHER System.
Eligibility Criteria
Inclusion Criteria
•The subject is at least 14 years of age at the time of informed consent and is sexually active
- The subject reports symptoms consistent with a suspected STD (sexually transmitted disease) such as abnormal discharge, genital itching, pain/discomfort during sexual intercourse or urination, and/or lower abdominal discomfort.
- If the subject is asymptomatic, the subject is known to be partners with, or a contact of, a person with a confirmed or suspected STD(s), is undergoing screening evaluation for a possible STD(s), and/or is scheduled for a routine exam that may include a pelvic exam
- The subject and/or legally authorized representative is willing to undergo the informed consent process prior to study participation (a minor will need the documented consent of his/her parent or legal guardian, unless the site has an IRB (institutional review board) approved waiver for parental consent for minors)
Exclusion Criteria
•A potential subject will be ineligible for clinical trial enrollment if the subject, clinician, or medical record reports any of the following:
- The subject took antibiotic medications within the last 21 days
- The subject is underage (as defined by the IRB (institutional review board) or state law), without the documented consent of her/his parent or legal guardian (exception: sites that have an IRBapproved waiver for parental consent for minors)
- The subject is determined by the investigator to be medically unsuitable for participation in this study (eg, medical history of concurrent illness that could result in an unacceptable risk to the subject) Concurrent participation in other clinical study(ies) may be acceptable, with approval by the investigator and sponsor.
Data sourced from ClinicalTrials.gov (NCT01733069). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.